New drug combo aims to tackle Hard-to-Treat HER2 cancers
NCT ID NCT07646626
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrink tumors and control the disease longer than current options. Participants must have tumors that cannot be removed by surgery or have spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SSGJ-705 (a bispecific antibody targeting PD-1 and HER2) and SSGJ-612 (an anti-HER2 antibody), with or without chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced HER2-positive cancers that have stopped responding to standard therapies.
What could go wrong
This is a mid-stage (Phase 2) trial with only 150 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors in many patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••